Events and Presentations
Upcoming Events
March 11, 2021
10:20 AM EST
10:20 AM EST
March 16, 2021
1:50 PM EDT
1:50 PM EDT
Past Events
February 26, 2020
8:00 AM EST
8:00 AM EST
January 13, 2020
4:30 PM PST
4:30 PM PST
January 10, 2020
8:00 AM EST
8:00 AM EST
November 6, 2019
8:00 AM EST
8:00 AM EST
September 12, 2019
8:00 AM EDT
8:00 AM EDT
August 7, 2019
8:00 AM EDT
8:00 AM EDT
June 3, 2019
8:00 AM EDT
8:00 AM EDT
May 8, 2019
8:00 AM EDT
8:00 AM EDT
May 7, 2019
9:00 AM EDT
9:00 AM EDT
March 6, 2019
8:00 AM EST
8:00 AM EST
Scientific & Medical Meetings
March 2, 2021
|
Source
Preliminary safety, antitumour activity and pharmacodynamic results of the Human Intratumoral Immunotherapy (HIT-IT) trial of MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions
|
ESMO TAT 2021.pdf 5.8 MB
|
November 11, 2020
|
Source
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors
|
|
August 26, 2020
|
ACIP COVID-19 Vaccine Presentation 963.8 KB
|
|
May 29, 2020
|
Source
A Phase 1 Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral (iTu) Injection Alone and in Combination with Durvalumab
|
|
May 29, 2020
|
Source
A Phase 1 Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral (iTu) Injection Alone and in Combination with Durvalumab
|
|
April 27, 2020
|
Source
A Phase 1/2, Open Label, Multicenter, Dose Escalation and Efficacy Study of mRNA 2416, A Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination with Durvalumab for Patients with Advanced Malignancies
|
|
October 16, 2019
|
Source
mRNA Medicines to Enable Intracellular, Membrane-Bound, and Extracellular Secreted Therapeutics
|
Zaks OTS 2019.pdf 4.7 MB
|
October 2, 2019
|
Source
Phase 1 Trial of an mRNA-based Combination Vaccine Against hMPV and PIV3
|
|
June 1, 2019
|
Source
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (Keynote-603)
|
|
June 1, 2019
|
Source
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (Keynote-603)
|